Abstract
Co-infection of hepatitis B virus (HBV) and hepatitis C virus (HCV) with human immunodeficiency virus (HIV) is associated with increased risk of hepatic complications and mortality. A retrospective study to estimate the proportion of HBV and HCV co-infections in Singapore was conducted using a clinical database. We included 3065 patients who were seen under the Clinical HIV Programme at the largest referral centre for HIV care between 2006 and 2017 and were tested for both HBV and HCV. Factors associated with HIV-HBV and HIV-HCV co-infections were determined using logistic regressions. The majority (86.3%) of HIV-infected patients were mono-infected, while 7.2% were co-infected with HBV, 6.0% with HCV, and 0.5% were co-infected with both HBV and HCV. The most common HCV genotype was GT1 (63%). Factors significantly associated with HBV co-infection in the multivariable model were: Aged 30–49 years and 50–69 years at HIV diagnosis, male gender, and HIV transmission through intravenous drug use (IDU). Independent factors associated with HCV co-infection were: Malay ethnicity, HIV transmission through IDU, and HIV diagnosis between 2006 and 2008. Behavioural risk factors such as IDU, as well as epidemiologic differences associated with co-infection, should inform further studies and interventions aimed at reducing viral hepatitis infection among HIV-infected individuals.
Highlights
Human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) are the most common chronic viral infections worldwide [1]
We investigated the epidemiological factors associated with HBV and HCV co-infection among HIV-infected patients in Singapore
After excluding 32 who had been tested positive for HBV and/or HCV more than one year before HIV diagnosis and subsequently tested negative, a total of 3065 HIV-infected patients constituted the final sample for this study
Summary
Human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) are the most common chronic viral infections worldwide [1] These three viruses share common modes of transmission, which include sexual transmission, sharing of needles with intravenous drug use (IDU), and transfusion of blood and blood products. The advent of tenofovir, lamivudine, and emtricitabine have led to significant improvements in reducing hepatic complications and related mortality Despite these advances, some studies continue to show that overall mortality and risk of hepatocellular carcinoma remains elevated in HIV-HBV co-infected populations compared to HIV or HBV mono-infected populations [3,4], while others have shown better prognosis with the advent of HAART [5]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.